Jabil enters FY2027 with AI-led growth and capacity risks

Transcript intelligence

What changed

The narrative moved from a raised FY2026 outlook and initial AI-capacity expansion to a FY2027 plan centered on $44.5 billion of revenue, $22.1 billion of AI revenue, broader manufacturing capacity and greater shareholder returns. Management also highlighted physical AI and a shift toward higher-margin automation and robotics, while the analysis flags new execution and supply-chain risks.

Guidance delta

Management projected FY2027 revenue of $44.5 billion, core margin of 6.1% and EPS of $17.55; the prior-quarter analysis had focused on the FY2026 outlook.

Key takeaways

• AI infrastructure remains the primary growth engine, with FY2027 AI revenue targeted at $22.1 billion, up 54% year over year.
• Management projected FY2027 revenue of $44.5 billion, up 24% year over year, with 6.1% core margin and $17.55 EPS.
• The asset-light model targets net CapEx of 1.5%–2% of revenue while free cash flow is expected to exceed $1.6 billion.
• Jabil plans roughly 4 million square feet of additional capacity and expects more than 700 million drug-delivery injectors in FY2027.
• Demand is broad across data centers, automotive, defense, healthcare and energy, but component shortages and execution remain material risks.

Management priorities

• Expand manufacturing capacity across the U.S., India, Mexico and Vietnam.
• Invest in factory automation, computer-vision inspection and AI-driven workflow tools.
• Pursue selective acquisitions and expand physical AI capabilities.
• Maintain disciplined share repurchases while preserving an investment-grade credit profile.